Trial Profile
A prospective observational study evaluating long-term use of Omalizumab in patients with persistent severe allergic asthma (PSAA).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 04 Jan 2017 New trial record